Radiation Oncologist
The Netherlands Cancer Institute, Netherlands
Prof. Dr. Rick Haas has been trained as a radiation-oncologist in the Netherlands Cancer Institute (NKI-AvL) from 1992 until 1997, where he remained as a staff member ever since. He has the privilege of also occupying a research position at the Department of Radiotherapy at the LUMC since January 2017, where he is appointed Professor since June 1st, 2020. Between 2002 and 2015 he was responsible for the training of radiotherapy residents at the NKI-AvL.
His focus lies on soft tissue sarcomas (STS) and lymphomas. He was the PI of the Phase I trial combining Pazopanib and radiotherapy in primary extremity STS (closed and published; NCT01985295). He is the PI of several phase II trials; the PASART-2 study (investigating the efficacy of the combination of pazopanib and 50 Gy preoperative RT; NCT02575066), the DOREMY study (investigating a dose reduction of preoperative RT in myxoid liposarcomas; NCT02106312) and a study on sarcoma patient derived xenografts, collecting a PDX and 2D/3D cell culture platform (NCT02910895). Finally, the phase III EORTC 62092 / 22092 trial (surgery alone versus surgery after neoadjuvant RT in primary retroperitoneal sarcomas; NCT01344018) has completed accrual and first results have been presented in The Lancet Oncology. In his preclinical in vitro studies, he investigates the RT fractionation sensitivity of STS cell lines, with the aim to generate iso-effective but less toxic regimens for the clinic. These investigations are expanded in vivo to both cell line derived and PDX models.
Rick Haas is married and he is the father of 3 children.